skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
LONDON – June 3rd, 2019 Informa Pharma Intelligence today announced that Duncan Emerton, PhD has joined the team in the position of Director. A global expert in biosimilars and the pharmaceutical/biotech space, Dr. Emerton is also a well-known speaker and thought-leader with an established reputation within the healthcare markets Informa Pharma Intelligence serves.

Dr. Emerton has more than 20 years of experience in the pharmaceutical industry, spanning roles in non-clinical and clinical R&D, sales, marketing, medical affairs, strategic consulting and business analysis. Most recently, Duncan was at FirstWord Group, where he was responsible for all syndicated disease analysis across a wide range of therapy areas, including respiratory, autoimmune, neurology, rare diseases and oncology.

“Much of my career has focused on working for and partnering with biopharma clients, including supporting strategy, research and bespoke consulting deliverables across varied market intelligence needs. In this new role within Informa Pharma Intelligence, I’m looking forward to supporting clients by utilizing Informa’s industry-leading data to deliver powerful intelligence solutions, strategy development needs, market research and much more.” said Dr. Emerton.

Before joining FirstWord Group, Dr. Emerton spent nearly a decade at Datamonitor Healthcare (part of the Informa Pharma Intelligence Family) where he worked in company analysis (PharmaVitae), disease analysis (cardiology and metabolism) and on the healthcare consulting team. Prior to that, Duncan held various roles at Pfizer and a number of other pharmaceutical companies, mainly focused on medical affairs and clinical R&D.

“We’re always looking to add the best talent to our team to ensure we never fail on our promise to clients that our experienced consulting team utilizes leading pharma intelligence and powerful insight generation expertise to support impactful, real-world decisions,” said Richard Veal, Global Director for Informa Pharma Consulting. “With Duncan on board, our clients will immediately benefit from his unique expertise across pharma, biotech and from his specialized knowledge across biosimilar markets. Our clients are consistently inquiring about our evolving offerings and market expertise, and having Duncan join the Informa Pharma Consulting team immediately bolsters our capability to meet these changing needs of our customers.”

About Informa Pharma Intelligence

Informa Pharma Intelligence powers a full suite of analysis products—Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.

Media Contact    
Diffusion PR for Informa Pharma Intelligence
informapharma@diffusionpr.com
646.571.0120


###


Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: